Calistoga Pharmaceuticals Presents Preclinical Data on CAL-120 at The AACR-EORTC-NCI Molecular Targets & Cancer Therapeutics Conference
11/17/2009 11:33:29 AM
More...
|
Calistoga Pharmaceuticals Presents Interim Clinical Efficacy Results from Ongoing Clinical Trial of CAL-101 at the International Workshop on Chronic Lymphocytic Leukemia
10/19/2009 8:58:25 AM
More...
|
Calistoga Pharmaceuticals Raises $30 Million in Series B Financing
5/5/2009 8:29:58 AM
More...
|
Calistoga Pharmaceuticals Announces Presentations on CAL-101 and CAL-120 at the American Association for Cancer Research Annual Meeting
4/22/2009 10:14:29 AM
More...
|
Calistoga Pharmaceuticals Announces Presentations on CAL-101 and CAL-120 at American Association for Cancer Research Annual Meeting
4/22/2009 9:28:22 AM
More...
|
Calistoga Pharmaceuticals Announces Appointment of Clifford J. Stocks as Chief Business Officer
3/11/2009 9:15:14 AM
More...
|
Calistoga Pharmaceuticals Release: CAL-101, an Oral p110d Isoform-Selective PI3 Kinase Inhibitor, Demonstrates Preclinical Activity in Hematologic Cancer Cells
12/9/2008 8:59:56 AM
More...
|
Calistoga Pharmaceuticals Appoints Carol G. Gallagher, Pharm. D., Chief Executive Officer
10/8/2008 7:42:46 AM
More...
|
Calistoga Pharmaceuticals Initiates First Oncology Clinical Trial of Novel PI3K Delta Inhibitor, CAL-101
7/10/2008 9:41:12 AM
More...
|
Calistoga Pharmaceuticals Initiates Its First Clinical Study of Novel Oral PI3K Delta Compound, CAL-101
3/11/2008 10:06:42 AM
More...
|
|